Exenatide-PD3, reported in The Lancet in early 2025, was the largest and longest trial of a GLP-1R agonist in Parkinsons disease: 194 patients, once-weekly exenatide, 96 weeks
H., Hilfinger, A., Howard, J
More recently, in CHD patients undergoing PCI, intravenous administration of probucol (500 mg twice daily, one day before and three days after surgery) increased serum GSH levels [244]
Noom GLP-1 Rx Plus Program GLP-1 treatment paired with Noom behavior change Program 2 Includes medication (if prescribed), ongoing care, and full program access